{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008882","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.632365+00:00","generated_at":"2026-06-01T06:28:07.337551+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GlycoMimetics Phase 3 uproleselan misses primary OS endpoint; positive subgroup in primary refractory AML","bullets":["Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.","In primary refractory AML (n=128), mOS improved to 31.2 vs 10.1 months (HR 0.58; 95% CI 0.37-0.91).","Safety consistent with chemotherapy; no new adverse event signals.","Company planning to engage regulators and NCI; Phase 2/3 study in frontline AML advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008882","json":"https://secwatch.observer/filing/0001558370-24-008882.json","markdown":"https://secwatch.observer/filing/0001558370-24-008882.md","text":"https://secwatch.observer/filing/0001558370-24-008882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/0001558370-24-008882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024008882/glyc-20240604x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:28:07.337551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}